Repligen | RGEN - Operating Profit


Repligen reported $19.98M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agilent USD 399M 46M Mar/2026
Align Technology USD 178.05M 46.66M Mar/2026
Bio Techne USD 75.49M 21.03M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Bruker USD 10.2M 66.1M Mar/2026
Charles River Laboratories USD 119.9M 44.08M Mar/2026
Danaher USD 1.34B 158M Mar/2026
Dentsply International USD 32M 506M Mar/2026
General Electric Aerospace USD 2.32B 549M Mar/2026
Henry Schein USD 182M 4M Mar/2026
Illumina USD 239M 17M Mar/2026
IQVIA Holdings USD 565M 2.11B Mar/2026
Mettler Toledo International USD 233.93M 118M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
Repligen USD 19.98M 13K Mar/2026
Revvity USD 82.77M 63.06M Mar/2026
Standard Biotools USD -21.92M 1.55M Dec/2025
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Waters USD 148M 122.52M Mar/2026
West Pharmaceutical Services USD 177.1M 14.6M Mar/2026